SEC Form 4 · accession 0001415889-18-000900
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lisa Bratkovich
Officer — CHIEF MARKETING OFFICER
Period of report
Jun 4, 2018
Accepted (ET)
Jun 6, 2018 · 8:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.45 | Jun 4, 2018 | A | 200,000 | A | — | Jun 3, 2028 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1One-third of the shares subject to the option vest on June 4, 2019, and the remaining shares subject to the option vest in a series of 24 equal monthly installments thereafter on each such vesting date.